演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

Efficacy and feasibility of ESHAP as salvage therapy for relapsed and refractory malignant lymphoma

演題番号 : PS-1-242

神山 祐太郎 (Yutaro Kamiyama):1、杉山 勝紀 (Katsuki Sugiyama):1、矢野 真吾 (Shingo Yano):1、島田 貴 (Takaki Shimada):1、矢萩 裕一 (Yuichi Yahagi):1、小笠原 洋治 (Yoji Ogasawara):1、高原 忍 (Shinobu Takahara):1、齋藤 健 (Takeshi Saito):1、笠間 絹代 (Kinuyo Kasama):1、横山 洋紀 (Hiroki Yokoyama):1、町島 智人 (Tomohito Machishima):1、鈴木 一史 (Kazuhito Suzuki):1、乾 由美子 (Yumiko Inui):1、土橋 史明 (Nobuaki Dobashi):1、薄井 紀子 (Noriko Usui):1、相羽 惠介 (Keisuke Aiba):1

1:Dept. Oncology and Hematology, Jikei Univ. School of Medicine, Japan

 

INTRODUCTION: There is a number of salvage regimen for relapsed or refractory malignant lymphoma (ML). ESHAP is frequently used regimen. We analyzed the clinical outcome of ESHAP.
PATIENTS AND METHODS: We performed a retrospective analysis of 67 patients with ML (36 DLBCL, 6 FL, 6 AITL, 12 PTCL-NOS, 1 ATL, 1 IVL, 1 B-cell lymphoma-NOS, 4 HL) who has been treated with ESHAP (with or without rituximab) between August 2004 and March 2013 in our hospital.
RESULTS: Median follow-up from diagnosis was 2.5 (0.2-19.8) years, and median age was 60 (31-74) years. Objective response rate (ORR) was 63.1%. Number of prior chemotherapeutic regimens was 1 regimen of 34 patients (51%), 2 regimens of 21 patients (31%), over 3 regimens of 11 patients. Eighteen patients among second line setting had DLBCL (52%). In this group, 17 patients (94.4%) received prior rituximab therapy, ORR was 76.5%, CR rate was 52.9%. Two patients (40.0% among eligible patients) received high dose chemotherapy followed by ASCT at second line setting. Stem cell mobilization in peripheral blood was completed for all patients who were intended to receive ASCT. Three patients stopped ESHAP because of toxicity; renal impairment, tumor lysis syndrome, severe infection. No treatment-related mortality was observed. One patient developed secondary malignancy, acute myelogenous leukemia.
CONCLUSION: ESHAP for refractory or relapsed ML was thought as feasible combination for Japanese. This results suggested that ESHAP has good efficacy as salvage regimen of relapsed DLBCL in post rituximab era, same as pre rituximab era.

前へ戻る